Andrx, InvaGen announce commercialization agreement

By Lisa Kerner

Erie, Pa., Jan. 23 - Andrx Corp. said it has entered into an agreement with InvaGen Pharmaceuticals Inc. to commercialize 11 Abbreviated New Drug Applications, with estimated total brand sales exceeding $13 billion for the trailing 12 months ended September 2005.

Abbreviated New Drug Applications for two of the products have been filed with the Food and Drug Administration, according to a company news release. Applications for the remaining products will be submitted during 2006 and through early 2007.

Under the agreement, InvaGen will be responsible for all formulation work, regulatory submissions and manufacture of each of the products.

Andrx will be responsible for sales and marketing efforts and coordination of any legal activities.

The agreement also provides that Andrx, at its option, may site transfer manufacturing of certain products to InvaGen's facility.

InvaGen is a generic pharmaceutical company based in Long Island, N.Y.

Andrx Corp., based in Fort Lauderdale, Fla., commercializes generic versions of controlled-release, niche and immediate-release pharmaceutical products, including oral contraceptives.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.